TAXOL - AN IMPORTANT NEW DRUG IN THE MANAGEMENT OF EPITHELIAL OVARIAN-CANCER

Authors
Citation
M. Markman, TAXOL - AN IMPORTANT NEW DRUG IN THE MANAGEMENT OF EPITHELIAL OVARIAN-CANCER, The Yale journal of biology & medicine, 64(6), 1991, pp. 583-590
Citations number
38
Language
INGLESE
art.tipo
Article
ISSN journal
0044-0086
Volume
64
Issue
6
Year of publication
1991
Pages
583 - 590
Database
ISI
SICI code
0044-0086(1991)64:6<583:T-AIND>2.0.ZU;2-Q
Abstract
Taxol, an antineoplastic agent isolated from the Pacific yew, has been demonstrated in three phase 2 clinical trials to have major activity (30 percent overall response rate) in patients with ovarian cancer ref ractory to cisplatin. The major toxicities associated with the agent a re neutropenia (dose-limiting), hypersensitivity reactions, peripheral sensory neuropathy, and cardiac arrhythmias. A recently reported phas e 1 trial of the combination of cisplatin and taxol has defined accept able doses for the two-drug combination to be tested against cisplatin and cyclophosphamide as frontline therapy of advanced ovarian cancer. Taxol has also been examined for intraperitoneal administration in pa tients with ovarian cancer, with a major pharmacokinetic advantage for peritoneal cavity exposure being demonstrated. Unfortunately, any fut ure development of taxol as an antineoplastic agent in the management of ovarian cancer will be dependent on the finding of an alternative s ource of the drug, as the current method of obtaining taxol from the b ark of the Pacific yew provides insufficient quantities for large-scal e clinical use.